These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 33143687)

  • 21. Internal Responsiveness of EQ-5D-5L and EORTC QLQ-C30 in Dutch Breast Cancer Patients during the First Year Post-Surgery: A Longitudinal Cohort Study.
    Vrancken Peeters NJMC; van Til JA; Huberts AS; Siesling S; Husson O; Koppert LB
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients.
    Kim EJ; Ko SK; Kang HY
    Qual Life Res; 2012 Sep; 21(7):1193-203. PubMed ID: 22012023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
    Doble B; Lorgelly P
    Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
    Yousefi M; Nahvijou A; Sari AA; Ameri H
    Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
    Meregaglia M; Borsoi L; Cairns J; Tarricone R
    Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping algorithms from QLQ-C30 to EQ-5D utilities: no firm ground to stand on yet.
    Crott R
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):569-76. PubMed ID: 24910212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
    Gray LA; Hernandez Alava M; Wailoo AJ
    BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
    Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
    Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after.
    Miret C; Orive M; Sala M; García-Gutiérrez S; Sarasqueta C; Legarreta MJ; Redondo M; Rivero A; Castells X; Quintana JM; Garin O; Ferrer M;
    Qual Life Res; 2023 Apr; 32(4):989-1003. PubMed ID: 36630024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
    Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
    J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
    [No Abstract]   [Full Text] [Related]  

  • 32. An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences.
    Crott R; Versteegh M; Uyl-de-Groot C
    Qual Life Res; 2013 Jun; 22(5):1045-54. PubMed ID: 22743734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
    van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
    Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mapping the EORTC QLQ-C30 and QLQ-H&N35 to the EQ-5D for head and neck cancer: Can disease-specific utilities be obtained?
    Beck ACC; Kieffer JM; Retèl VP; van Overveld LFJ; Takes RP; van den Brekel MWM; van Harten WH; Stuiver MM
    PLoS One; 2019; 14(12):e0226077. PubMed ID: 31834892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey.
    Longworth L; Yang Y; Young T; Mulhern B; Hernández Alava M; Mukuria C; Rowen D; Tosh J; Tsuchiya A; Evans P; Devianee Keetharuth A; Brazier J
    Health Technol Assess; 2014 Feb; 18(9):1-224. PubMed ID: 24524660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea.
    Kim SH; Kim HJ; Lee SI; Jo MW
    Qual Life Res; 2012 Aug; 21(6):1065-73. PubMed ID: 21947656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.
    Versteegh MM; Leunis A; Luime JJ; Boggild M; Uyl-de Groot CA; Stolk EA
    Med Decis Making; 2012; 32(4):554-68. PubMed ID: 22114301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study.
    Jiang L; Zhou H; Yang Q; Luo X; Huang D
    Qual Life Res; 2024 Mar; 33(3):805-816. PubMed ID: 38148367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30.
    Kemmler G; Holzner B; Kopp M; Dünser M; Margreiter R; Greil R; Sperner-Unterweger B
    J Clin Oncol; 1999 Sep; 17(9):2932-40. PubMed ID: 10561373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.